Torino ALS Center (CRESLA)

University of Torino

The Torino ALS Center (CRESLA) performs basic and clinical research, while at the same time providing care for ALS patients.

Cresla_footer
University of Torino

Our centre is based in the largest public hospital in Italy (the “Città della Salute e della Scienza” hospital of Torino). We follow about 350 patients each year, both locally and nationwide. We have a diagnostic laboratory and a molecular genetics laboratory. Our scientific studies include both clinical and basic research of ALS. In the last decade, we have participated in 5 large international randomized clinical trials on innovative drugs in ALS. We have a multidisciplinary group and a daily ALS clinic. We also provide psychological, neuropsychological and neurophysiological services.

Contact
Location
University of Turin, Turin, Via Cherasco 15, 10126, Torino, Italy

Our Specialists

Adriano Chiò

Professor of Neurology

Adriano Chiò is a neurologist currently working in Torino, Italy. He is […]

Adriano Chiò
Current trials
Active
Phase ii

CARDINALS

Industry trial
The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms. Researchers will also test the safety and tolerability of the study drug and how the body responds to it. The study drug is a liquid that is swallowed 2 times a day.
Read more
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Completed
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more